FDA Approved: VYVGART HYTRULO — Supplemental Application (argenx US)

View source ↗

Summary

The FDA approved a supplemental application for Vyvgart HYTRULO (efgartigimod alfa and hyaluronidase) submitted by argenx US.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• VYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE (HUMAN RECOMBINANT))

Snippet

SUPPL AP for VYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE (HUMAN RECOMBINANT))